Veralto Execs Sell $6.6M as Earnings Streak Continues
Four consecutive EPS beats haven't moved Veralto's stock, which is up just 3% year-to-date versus 13.1% for the S&P 500. Five executives sold $6.6M in shares over 90 days with no open-market purchases
Veralto Execs Sell $6.6M as Earnings Streak Continues
NEW YORK, November 13 —
Four consecutive EPS beats have not bought Veralto Corporation (VLTO) much goodwill from the market, and in the 18 days since the latest one, the company's top executives answered with their wallets. The CEO sold before the print; the segment heads and chief accounting officer sold after. Net insider purchases over the period: zero.
- Q3 2026 adjusted EPS of $1.18 beat the $1.10 consensus by 7.3%; revenue of $1.51B topped estimates by 0.7% [source]
- VLTO up ~3% year-to-date vs. 13.1% for the S&P 500; shares trade at 24.3x forward earnings, $117.81
- $6.64M in net insider sales over the past 90 days across five executives, $0 in open-market purchases
Four Beats, Persistent Discount
Veralto makes water quality instrumentation and treatment chemicals under the Hach, Trojan Technologies, and ChemTreat brands, plus marking, coding, and packaging design software under Videojet, Esko, and Pantone. These are sticky, industrial businesses with 59.8% gross margins and $763 million in trailing free cash flow. The company has beaten EPS consensus in every quarter since at least Q3 2025, with surprises ranging from 6% to nearly 10%, and has cleared revenue estimates in three of four. Yet the stock's 10-percentage-point lag to the S&P 500 year-to-date implies the market is not re-rating operational consistency. At 24.3x forward earnings, it may already have priced the execution record in.
The Selling Pattern After the Print
The sequence matters. CEO Jennifer Honeycutt sold 7,098 shares at $105.00 on October 23, six days before the Q3 release, netting $745,290 on options struck at $28.76. The day after the print, SVP Strategy Surekha Trivedi sold 36,427 shares at $108.89 for roughly $3.97 million, also from deep-in-the-money options. Chief Accounting Officer Bernard Skeete followed on November 2 at $112.58; SVP PQI Mattias Bystrom sold 9,069 shares at $116-plus on November 3; SVP Water Quality Melissa Kapity sold 5,146 shares at $118.06 on November 10. All five transactions were option exercises into open-market sales. All five were one-directional. The bull case for routine monetization is straightforward, these are low-strike options accumulated over years, but the absence of a single open-market purchase across five executives in a 90-day window is a data point, not noise.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| VLTO | $28.7B | 24.2x | +18.9% |
| RVTY | $17.2B | 25.8x | +69.3% |
| FTV | $20.2B | 20.4x | +31.5% |
| EG | $15.8B | 7.0x | +29.5% |
| CPAY | $29.6B | 14.6x | +63.4% |
| BALL | $17.0B | 14.6x | +36.4% |
What Needs to Change the Math
Veralto carries $1.78 billion in cash against $3.12 billion in total debt, a net debt position of $1.34 billion, and trailing revenue of $5.80 billion growing at 7.5%. The analyst consensus target of $124.63 implies modest upside from the current $117.81. The bull case requires either multiple expansion, unlikely if the market continues treating VLTO as a low-growth industrial, or an acceleration in revenue growth beyond the current 7.5% clip that forces a re-rate. The number to watch next quarter is revenue growth relative to the PQI segment, which serves food, beverage, and pharmaceutical packagers under margin pressure. If that segment holds that pace, the earnings streak continues. If it stalls, the insiders' timing will look prescient. Run the free Veralto Corporation deep-dive →
Current fundamentals, valuation and filing history for Veralto Corporation (VLTO) are tracked on its Basis Report page.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
What was Veralto's Q3 earnings result?
Veralto's Q3 2026 adjusted EPS of $1.18 beat the $1.10 consensus estimate by 7.3%, while revenue of $1.51B topped estimates by 0.7%. This marks the company's fourth consecutive quarter of beating EPS consensus.
Why are Veralto insiders selling?
Five Veralto executives sold $6.6M in shares over 90 days, all from exercising deep-in-the-money options accumulated over years. CEO Jennifer Honeycutt sold before the earnings print on October 23, while segment heads and the chief accounting officer sold after, with zero open-market purchases across the group.
How has Veralto stock performed?
Veralto is up just 3% year-to-date versus 13.1% for the S&P 500, trailing the broader market by 10 percentage points. The stock trades at 24.3x forward earnings, which may have already priced in the company's consistent earnings execution.
What does Veralto do?
Veralto makes water quality instrumentation and treatment chemicals under brands including Hach, Trojan Technologies, and ChemTreat, plus marking, coding, and packaging design software under Videojet, Esko, and Pantone. These sticky industrial businesses have 59.8% gross margins and generated $763 million in trailing free cash flow.
What's the outlook for Veralto's stock?
The analyst consensus target of $124.63 offers modest upside from the current $117.81. The bull case requires either multiple expansion or revenue growth acceleration beyond the current 7.5% clip to force a meaningful re-rating.
Veralto Corporation delivered its fourth consecutive EPS beat in Q3 2026, yet the stock has gained only about 3% year-to-date against the S&P 500's 13%. In the two weeks since that earnings release, every tracked insider — CEO, two SVPs, and the Chief Accounting Officer — sold shares, logging $6.64 million in net sales with zero purchases.